We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 34.00 | 33.10 | 34.90 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
03/1/2020 09:59 | Adams Increases Stake In Circassia Pharmaceuticals Fri, 3rd Jan 2020 09:50 Alliance News (Alliance News) - Adams PLC on Friday said it has raised its holding in Circassia Pharmaceuticals Ltd. Adams, which invests in AIM-listed companies, bought 2.4 million shares on Thursday at an average price of 19.0 pence per share for a total investment of GBP456,229. It brings its holdings in Circassia to 3.1 million shares, an 0.8% stake. Circassia shares were up 1.4% at 19.70p on Friday morning in London. The follow-on investment comes after Circassia early in December forecast revenue for 2019 to be between GBP60 million to GBP65 million compared to the GBP48.3 million in 2018. Following the purchase investment, Adams has a cash balance of around GBP1 million, it said. Shares in Adams were trading flat at 5.00p each on Friday morning in London. | pro_s2009 | |
03/1/2020 08:12 | Thats what makes me think the trading update is within the next couple of weeks. Once people outside of the insiders get a sniff of the figures, and if they are good, then they start buying up as much as they can. | pro_s2009 | |
03/1/2020 00:36 | Well, it looks like the overhang at 19p is cleared. hopefully the trading update comes next week or the week after and its a strong one. If sales are strong, as hes been suggested, then the trading update should spark some serious buying. | pro_s2009 | |
02/1/2020 16:18 | Off we go again more institutional buying,nice to see a bit of blue. | 100egs | |
02/1/2020 15:41 | make that another 5.5 m | timmy11 | |
02/1/2020 15:40 | someone bought 5 and half million shares | timmy11 | |
02/1/2020 15:40 | Moving up after those big trades went through | pro_s2009 | |
31/12/2019 10:32 | Could be, its one of my selections for 2020. Happy really we enter 2020 at 19p levels, allows for plenty of upside running during the next year. Expecting a January trading update, so that should hopefully start things rolling in terms of share price appreciation. | pro_s2009 | |
31/12/2019 10:25 | Reckon this may well be a new year tip..just look at the broker notes here. | pre | |
29/12/2019 10:49 | Don't forget to get your top 5 picks into the annual UK Stock Challenge for 2020. Just click on the Entry tab. . | pro_s2009 | |
27/12/2019 11:50 | What were last week's tips costax ? | arab3 | |
27/12/2019 11:24 | Idp looks ready for a rally | costax1654x | |
24/12/2019 08:55 | Circassia Pharmaceuticals refutes claims over PPHN product Circassia acquired exclusive commercialisation rights to LungFit PH in the United States and China Circassia Pharmaceuticals PLC - Circassia Pharmaceuticals receives termination notice for licencing agreement One in 500 newborns suffers from the breathing condition Circassia Pharmaceuticals PLC (LON:CIR) has rejected claims by a licensing partner that it materially breached terms of their agreement over a product for babies with breathing difficulties. The AIM-listed company has received a notice from BeyondAir, previously known as AIT Therapeutics, to terminate the agreement. In January, Circassia acquired exclusive commercialisation rights to BeyondAir's LungFit PH product, initially called AirNOvent, in the United States and China. READ: Circassia completes managerial changes as Johnson becomes executive chairman LungFit PH is a treatment for persistent pulmonary hypertension (PPHN) in newborns. PPHN occurs when the pressure in the blood vessels of a baby’s lungs remains high after birth, which can restrict the amount of oxygen flowing around the body. It is thought to occur in around one in 500 births. Circassia has refuted the claim of a material breach of the agreement. “The company will enforce its rights under the agreement and defend its position vigorously,” it added in a statement. House broker Peel Hunt estimated that "even in a worst-case scenario" removing BeyondAir's contribution from its sales forecasts without any cost offset, "Circassia still turns EBITDA positive in 2020, and maintains a positive cash balance across our forecast period". ........ | pro_s2009 | |
24/12/2019 08:27 | That's the problem with advfn, they switch off at end of trading day. I always check with LSE, it's laggy but that trade was reported 15.11.20 | minja19 | |
24/12/2019 08:22 | Yes, definite accumulation going on. | pro_s2009 | |
23/12/2019 15:25 | Buying continues, lets hope the next news is a resolution of the dispute with BeyondAir. Although the dispute does not effect the immediate short term, as sales were not due to come in until late 2020, it would of course be a boost to the medium term if this was resolved and the potential sales revenue for 2021 reinstated. | pro_s2009 | |
23/12/2019 10:56 | Picked up a few more for myself, as I am expecting the next RNS to announce settlement in CIR's favour. | minja19 | |
23/12/2019 09:56 | Decent buying today, long may it continue | pro_s2009 | |
23/12/2019 09:32 | B B B Busy Bots Buying, all morning | minja19 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions